Sarepta Therapeutics reported Exondys 51 sales of $35 million for the second quarter, nicely above the consensus estimate of $23 million.
Exondys 51 sales guidance for the year was raised to a range of $125-130 million from “greater than” $95 million. The new guidance essentially assumes no Exondys 51 sales growth in the second half of the year and no revenue from the recently announced compassionate use program, both of which are unlikely. Sarepta’s new CEO Doug Ingram is being conservative.
About the Author Reprints
